Testosterone Replacement Therapy and Liraglutide Effects on Weight Loss in Hypogonadism.

NCT03619330 · Completed

Last updated 2026-05-28

This clinical trial tested whether testosterone replacement therapy and liraglutide help reduce symptoms of hypogonadism in adults with both hypogonadism and obesity.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 30 people

Who can join Ages 18–65 · male only

Timeline Started 2014-12 · est. completion 2015-08

Where 1 site · Slovenia

What this study is testing ClinicalTrials.gov NCT03619330 ↗

Description as written by the study sponsor.

The purpose of this study was to compare the effects of liraglutide and testosterone replacement therapy on features of hypogonadism and weight loss in obese men with persistent features of hypogonadism after unsuccessful lifestyle measures.

Treatments tested

liraglutide also known as Victoza 6 mg/ml solution for injection in pre-filled pen Drug

In the liraglutide group liraglutide was initiated at a dose of 1.2 mg injected sc once per day and increased to 3 mg/day after 1 week.
Testosterone also known as Androtop gel Drug

In the testosterone group Androtop gel 5 grams (50 mg of testosterone) was applied once a day on a dry skin.

Main thing measured	The main outcome was improvements of symptoms related to hypogonadism
Sponsor	University Medical Centre Ljubljana
Conditions studied	Hypogonadism, Obesity
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03619330 ↗